Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial
Background Intratumoral oncolytic herpes simplex virus 2-GM CSF (OH2) injection has shown safety and antitumor efficacy in patients with solid tumors. Here, we examined the safety and efficacy of OH2 as a single agent or in combination with HX008, an NMPA-approved PD-1 inhibitor, in locally advanced...
Saved in:
Main Authors: | Lu Zhang, Shu Li, Jing Huang, Yan Wu, Liang Han, Tian Gao, Qingxia Fan, Suxia Luo, Binlei Liu, Lixin Zhou, Xinyu Wang, Ling Jia, Jianhua Shi, Zhichao Tan, Zhengfu Fan, Sijuan Ding, Chujie Bai, Ruifeng Xue, Jiayong Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/1/e010543.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
by: Juan Li, et al.
Published: (2025-02-01) -
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
by: Ann W. Silk, et al.
Published: (2016-09-01) -
Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer
by: Marketa Skalickova, et al.
Published: (2025-01-01) -
Energy transfer process in the reaction system NH2OH-OH-NaOH-CU(II)−Eu(III) / thenoyltrifluoroacetone
by: Stefan Lis, et al.
Published: (2005-01-01) -
Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis
by: William J Murphy, et al.
Published: (2023-01-01)